Infectious Diseases (all articles)
Persistent COVID-19 symptoms in a community study of 606,434 people in England.
26 Apr, 2022 | 08:48h | UTC
Commentary on Twitter
Thirty-eight percent of participants from a community-based study of symptoms following COVID-19 reported persistent symptoms that lasted 12 weeks or more, according to an article published in @NatureComms. https://t.co/sAEutdOkSS pic.twitter.com/oCyyXGIRbk
— Nature Portfolio (@NaturePortfolio) April 20, 2022
Cohort Study: Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations.
26 Apr, 2022 | 08:21h | UTCNews Release: Study suggests association between severe COVID-19 and long-term mental health outcomes 16 months after an illness – Lancet
Commentary: Lasting depression and anxiety can follow severe case of Covid – NBC News
Commentary on Twitter (thread – click for more)
https://twitter.com/COVIDMENT/status/1513511696979329024
Yes, relapses after Paxlovid happen — now what?
26 Apr, 2022 | 08:18h | UTCYes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations
Commentary on Twitter
Some additional thoughts about relapsing Covid19 after treatment with Paxlovid.
Bottom line — *lots* of unknowns, starting w/ how often it happens.
Looking forward to @pfizer sharing further data on the relapsing cases from their EPIC-HR study. https://t.co/1MMhqn4elw
— Paul Sax (@PaulSaxMD) April 25, 2022
Why does the Omicron variant largely spare olfactory function? implications for the pathogenesis of anosmia in COVID-19.
26 Apr, 2022 | 08:05h | UTC
Cohort Study: Effectiveness of homologous vs. heterologous booster doses for an inactivated SARS-CoV-2 vaccine.
26 Apr, 2022 | 08:06h | UTCCommentaries:
COVID-19 vaccine booster strategy: striving for best practice – The Lancet Global Health
Covid-19: Mix and match booster vaccination approach offers best protection, study reports – The BMJ
Commentary on Twitter
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study https://t.co/0k7WlphoDV Heterologous booster provided ⬆️ protection than homologous one, especially when Coronavac vaccine had been used.
— Carlos del Rio (@CarlosdelRio7) April 25, 2022
Consensus for the treatment of tinea pedis.
26 Apr, 2022 | 08:02h | UTC
Podcast: Curing Hepatitis C.
26 Apr, 2022 | 07:47h | UTC#329 Curing Hepatitis C – The Curbsiders
WHO: Multi-country – acute, severe hepatitis of unknown origin in children.
25 Apr, 2022 | 01:13h | UTCMulti-Country – Acute, severe hepatitis of unknown origin in children – World Health Organization
Commentaries:
WHO says 12 countries have reported unusual cases of hepatitis in kids – STAT
At least one child has died from mystery strain of severe hepatitis, WHO confirms – The Guardian
Related:
CDC Alerts Providers to Hepatitis Cases of Unknown Origin – Centers for Disease Control and Prevention AND Guidance: Recommendations for Adenovirus Testing and Reporting of Children with Acute Hepatitis of Unknown Etiology – Centers for Disease Control and Prevention
Could Mysterious Hepatitis Cases be Triggered by COVID-19? – Health Policy Watch
U.S., U.K. investigating unusual cases of hepatitis in young children – STAT
Mysterious liver illness seen in kids in US, Europe – Associated Press
Cohort Study: COVID-19 vaccination during early pregnancy was not associated with increased risk of congenital fetal anomalies.
25 Apr, 2022 | 00:59h | UTCCommentaries:
COVID vaccine in early pregnancy not tied to birth defects – CIDRAP
No Sign That COVID Vaccine in Pregnancy Raises Birth Defect Risk – HealthDay
SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity.
25 Apr, 2022 | 00:56h | UTCRelated Study:
Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open AND Commentaries: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services AND COVID-19 infection may offer similar immunity as vaccination – CIDRAP
Systematic Review: The performance of wearable sensors in the detection of SARS-CoV-2 infection.
25 Apr, 2022 | 00:55h | UTC
Commentary on Twitter
A missed opportunity for Covid early detection and tracking, inexpensively, passively, at scalehttps://t.co/4cDxlps7AM systematic review of wearable sensors (smartwatch or fitness bands worn or owned by > 80 million Americans) @LancetDigitalH pic.twitter.com/sy1rArB5fE
— Eric Topol (@EricTopol) April 22, 2022
Under a (CC BY 4.0) License
WHO recommends highly successful COVID-19 therapy (nirmatrelvir-ritonavir) and calls for wide geographical distribution and transparency from originator.
22 Apr, 2022 | 09:36h | UTCSee also:
A living WHO guideline on drugs for covid-19 – The BMJ
Therapeutics and COVID-19: living guideline – World Health Organization
Related:
Commentary on Twitter
🔥 Our latest @WHO living guidance on drugs for #COVID19, with new recommendations for nirmatrelvir-ritonavir & updated recommendation for remdesivir in non-severe illness.@bmj_latest: https://t.co/KuJjwzeTPV@WHO: https://t.co/n3iQx3pdmY
@theMAGICapp: https://t.co/dA7YYzeAZ1 pic.twitter.com/LvAhJf70UY
— Arnav Agarwal (@ArnavAgarwalMD) April 21, 2022
CDC alerts providers to hepatitis cases of unknown origin.
22 Apr, 2022 | 09:34h | UTCCommentaries:
CDC issues health advisory about acute hepatitis in children – CNN
CDC Issues Alert for Hepatitis in Children With Adenovirus Infection – WebMD
Related:
Could Mysterious Hepatitis Cases be Triggered by COVID-19? – Health Policy Watch
U.S., U.K. investigating unusual cases of hepatitis in young children – STAT
Mysterious liver illness seen in kids in US, Europe – Associated Press
Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries.
22 Apr, 2022 | 09:28h | UTC
Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.
22 Apr, 2022 | 09:21h | UTCInvited Commentary: Game-changing study of second-line HIV treatment – The Lancet HIV (free registration required)
Original Study: Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine
Commentary on Twitter
Efficacy and safety of DTG or DRV in combination with 3TC + ZDV or TDF for second-line treatment of HIV infection (NADIA)… https://t.co/XajA2rLzsp DTG & DRV-based ART maintain good viral suppression during 96 wks; DTG non-inferior to DRV but ⬆️risk of resistance in 2rd-line Rx.
— Carlos del Rio (@CarlosdelRio7) April 21, 2022
RCT: Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for prevention of Covid-19.
21 Apr, 2022 | 10:29h | UTC
Commentary on Twitter
AZD7442 (tixagevimab/cilgavimab) found to have about 76% efficacy in preventing symptomatic Covid-19 infection. https://t.co/8tmvz3xI4I pic.twitter.com/fOegZjBRA6
— NEJM (@NEJM) April 20, 2022
[News release – not published yet] New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV.
21 Apr, 2022 | 10:28h | UTCRelated Study: Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link to abstract – $ for full-text)
Cohort study: COVID-19 infection granted patients strong and long-lasting protection from reinfection.
21 Apr, 2022 | 10:20h | UTCNews Release: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services
Original Study: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open
Commentary: COVID-19 infection may offer similar immunity as vaccination – CIDRAP
Commentary on Twitter
This US cohort study found that unvaccinated individuals with prior symptomatic #COVID19 had 85% lower risk against recurrent COVID-19 compared to unvaccinated individuals without prior infection, for up to 9 months, through November, 2021. https://t.co/1qHCFmGqXG
— JAMA Network Open (@JAMANetworkOpen) April 20, 2022
SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents.
21 Apr, 2022 | 10:23h | UTCEditorial: Communicating the Benefits of Vaccination in Light of Potential Risks
Studies highlight meningitis vaccine’s potential against gonorrhea.
20 Apr, 2022 | 10:06h | UTCCommentary: Studies highlight meningitis vaccine’s potential against gonorrhea – CIDRAP
News Release: Threat of untreatable gonorrhoea could be tackled using an existing meningitis vaccine – The Lancet
Study 1: Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Study 2: Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Covid hasn’t given up all its secrets. Here are 6 mysteries experts hope to unravel.
20 Apr, 2022 | 09:57h | UTCCovid hasn’t given up all its secrets. Here are 6 mysteries experts hope to unravel – STAT
Expert Guidance: Strategies to prevent central line-associated bloodstream infections in acute-care hospitals.
20 Apr, 2022 | 10:13h | UTC
Commentary on Twitter
Prevention of central line-associated bloodstream infections in acute-care hospitals- 2022 updatehttps://t.co/o3AReYvJIu pic.twitter.com/QsgYYezhqj
— K Pavithran (@drkpavithran) April 19, 2022
Article under a http://creativecommons.org/licenses/by/4.0/ license
A nonrandomized controlled study found awake prone position (median of 4.2 hours per day) may not benefit hospitalized adults with Covid-19.
20 Apr, 2022 | 09:56h | UTCCommentaries:
Study suggests worse outcomes for awake COVID patients in prone position – CIDRAP
Putting Hospitalized COVID Patients on Their Belly May Not Be a Good Idea After All – HealthDay
Related:
RCT: Prone positioning of patients with moderate hypoxia due to COVID-19 – medRxiv
Commentary on Twitter (thread – click for more)
Important negative study: non randomized trial finds no clinical benefit to awake proning vs usual care in COVID
No difference in rates of intubation, length of stay, or 28 day mortality
Medicine is humbling. This emphasizes the importance of trials
📄https://t.co/ksh9Ic9XBL
1/ pic.twitter.com/sjHHv4WQs8— Nick Mark MD (@nickmmark) April 18, 2022
AAOS Guideline: Prevention of surgical site infections after major extremity trauma.
19 Apr, 2022 | 02:35h | UTCEvidence Review: Prevention of Surgical Site Infection After Extremity Trauma (2022)
Video: Here’s what we know about COVID-19’s impact on the brain.
19 Apr, 2022 | 02:22h | UTCHere’s what we know about COVID-19’s impact on the brain – Science
Related:
SARS-CoV-2 is associated with changes in brain structure in UK Biobank – Nature
Nervous system consequences of COVID-19 – Science
The COVID generation: how is the pandemic affecting kids’ brains? – Nature
Assessment of Cognitive Function in Patients After COVID-19 Infection – JAMA Network Open